Fundamentally Strong, Technicals Not Yet Positive: Novavax Inc. (NVAX)

On June 14, Novavax Inc. (NVAX), a biotechnology company, announced that its NVX-CoV2373 vaccine achieved 90.4% effectiveness in the third phase of the clinical trial against Coronavirus. Furthermore, this drug is 100% protective against moderate to severe diseases. Novavax plans to apply for FDA approval by the third quarter of this year. There will be […]

Investors Are Once Again Showing Interest In Vaccine Stocks

Once again, pharmaceutical companies related to Covid-19 vaccines have been quite closely related. Novavax Inc. (NVAX) leapt by +2.93% to $120.27 on Tuesday. The U.S. biotechnology firm’s latest coronavirus vaccine candidate could be accepted next year, subject, of course, to good outcomes from the recently completed Phase 3 clinical trial. Pfizer Inc. (PFE) was up […]